Keyword Analysis & Research: kras g12c


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
kras g12c0.990.56432429
kras1.920.34653534
g12c0.9116312314

Keyword Research: People who searched kras g12c also searched

Keyword CPC PCC Volume Score
kras g12c0.660.4197655

Search Results related to kras g12c on Search Engine

  • The path to the clinic: a comprehensive review on direct KRAS G12C

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767686/

    WEBJan 19, 2022 · Analyzing amino acid-specific KRAS mutations in the three cancer types responsible for most KRAS mutations, the most common KRAS mutation in NSCLC adenocarcinoma subtype is KRAS G12C (glycine to cysteine) (33.4%), while the most common KRAS mutation in colon and rectal adenocarcinoma and pancreatic ductal …

    DA: 43 PA: 95 MOZ Rank: 86

  • The KRAS-G12C inhibitor: activity and resistance - Nature

    nature.com

    https://www.nature.com/articles/s41417-021-00383-9

    WEBSep 1, 2021 · The KRAS-G12C inhibitor: activity and resistance. Jiao Liu, Rui Kang & Daolin Tang. Cancer Gene Therapy 29 , 875–878 ( 2022) Cite this article. 60k Accesses. 57 Citations. 146 Altmetric....

    DA: 53 PA: 80 MOZ Rank: 7

  • KRAS mutation: from undruggable to druggable in cancer

    nature.com

    https://www.nature.com/articles/s41392-021-00780-4

    WEBNov 15, 2021 · Excitingly, AMG510 was the first drug-targeting KRAS (G12C) to be approved for clinical use this year. This review summarises the most recent understanding of fundamental aspects of KRAS, the...

    DA: 49 PA: 60 MOZ Rank: 48

  • KRAS G12C Mutations in NSCLC: From Target to Resistance

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196854/

    WEBMay 21, 2021 · A better understanding of the role of KRAS and its different mutations has led to the development of specific small-molecule inhibitors able to target KRAS G12C, an oncogenic driver mutation in a number of cancers, including non-small cell lung cancer.

    DA: 22 PA: 12 MOZ Rank: 40

  • KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

    nejm.org

    https://www.nejm.org/doi/full/10.1056/NEJMoa1917239

    WEBSep 20, 2020 · The KRAS p.G12C mutation occurs in 13% of non–small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and...

    DA: 30 PA: 24 MOZ Rank: 40

  • Comprehensive pan-cancer genomic landscape of KRAS altered …

    nature.com

    https://www.nature.com/articles/s41698-022-00334-z

    WEBDec 9, 2022 · We performed a pan-cancer analysis of KRAS -altered samples from 426,706 adult patients with solid or hematologic malignancies using comprehensive genomic profiling; additional analyses included...

    DA: 10 PA: 29 MOZ Rank: 58

  • Landscape of KRASG12C, Associated Genomic Alterations, and

    ascopubs.org

    https://ascopubs.org/doi/10.1200/PO.21.00245

    WEBKRAS G12C was most prevalent in patients with non–small-cell lung cancer, appendiceal, colorectal, tumor of unknown origin, small bowel, and pancreatic cancers. KRAS G12C tumors were genomically distinct from KRAS non-G12C tumors, including variations in STK11, KEAP1, and other gene frequencies.

    DA: 51 PA: 34 MOZ Rank: 41

  • KRAS G12C inhibition in colorectal cancer - The Lancet

    thelancet.com

    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00652-5/fulltext

    WEBDec 14, 2021 · KRASG12C inhibition in colorectal cancer. Per Pfeiffer. Camilla Qvortrup. Published: December 14, 2021 DOI: https://doi.org/10.1016/S1470-2045 (21)00652-5. KRASG12C inhibition in colorectal cancer. For years, patients with metastatic colorectal cancer were considered and treated as a single biological entity.

    DA: 16 PA: 74 MOZ Rank: 4

  • Targeting KRAS G12C: from inhibitory mechanism to modulation …

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669705/

    WEBNov 12, 2020 · Recent advances in medicinal chemistry have established inhibitors targeting KRAS (G12C), a mutation found in ~13% of lung adenocarcinomas and, at a lower frequency, in other cancers.

    DA: 57 PA: 38 MOZ Rank: 36

  • Sotorasib is First KRAS Inhibitor Approved by FDA - NCI

    cancer.gov

    https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-sotorasib-lung-cancer-kras

    WEBJun 25, 2021 · The CodeBreaK 100 trial, funded by Amgen and NCI, is testing sotorasib (previously called AMG510) as a treatment for people with solid tumors that have KRAS G12C. The mutation, a hallmark of damage from cigarette smoke, is …

    DA: 58 PA: 46 MOZ Rank: 59